The U.S Food and Drug Administration has granted Expedited Access Pathway status to the Wearable Artificial Kidney (WAK) after the device performed successfully in its first U.S. clinical trial, at UW Medical Center in Seattle.
Despite technical issues that halted the trial early, the FDA signaled its support for keeping research and development of the device fast-tracked as its components are redesigned.
More than 600,000 Americans have end-stage kidney disease, whose annual mortality rate is...
More